Nintedanib (Ofev®)

Assessment Status Assessment Process Complete
Drug Nintedanib
Brand Ofev®
Indication Indicated in adults for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
Assessment Process
Rapid review commissioned 30/01/2015
Rapid review completed 18/02/2015
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 10/09/2015
NCPE assessment completed 22/02/2016
NCPE assessment outcome Reimbursement Not Recommended at the Submitted Price.

Technical Summary

The HSE has approved reimbursement following confidential price negotiations June 2017.